Biological drugs targeting the immune response in the therapy of psoriasis

Biologics: Targets and Therapy

Volumn 2, Issue 4, 2008, Pages 687-697

  Pastore, Saveria ^a   Gubinelli, Emanuela ^a   Leoni, Luca ^a   Raskovic, Desanka ^a   Korkina, Liudmila ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

Efalizumab; Etanercept; Immune mediated inflammation; Infliximab; Psoriasis

Indexed keywords

EID: 70449439786     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Baumgarth N, Bevins CL. 2007. Skin deep but complex. Nature, 449:551-3.
2. Boehncke WH, Brasie RA, Barker J, et al. 2006. Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus. J Eur Acad Dermatol Venereol, 20:988-98.
3. Bongartz T, Sutton AJ, Sweeting MJ, et al. 2006. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized trials. JAMA, 295:2275-85.
4. Bruch-Gerharz D, Schnorr O, Suschek C, et al. 2003. Arginase 1 overexpression in psoriasis. Limitation of inducible nitric oxide synthase activity as a molecular mechanism for keratinocyte hyperproliferation. Am J Pathol, 162:203-11.
5. Cassano N, Loconsole F, Galluccio A, et al. 2006. Once-weekly administration of high-dosage etanercept in patients with plaque psoriasis: results of a pilot experience (power study). Int J Immunopathol Pharmacol, 19:823-7. Chaudhari U, Romano P, Mulcahy LD, et al. 2001 Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet, 9271:1842-47.
6. Dziadzio M, Smith R. 2007. Meta-analysis is no substitute for a comprehensive national registry. Clin Rheumatol, 26:1134-5.
7. Dubertret L, Sterry W, Bos JD, et al. 2006. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol, 155:170-81.
8. Girolomoni G, Pastore S, Albanesi C, et al. 2002. Targeting tumor necrosis factor-ffas a potential therapy in skin inflammatory skin diseases. Curr Opin Investig Drugs, 3:1590-5.
9. Gisondi P, Gubinelli E, Cocuroccia B, et al. 2004. Targeting tumor necrosis factor-ffin the therapy of psoriasis. Curr Drug Targets Inflamm Allergy, 3:175-83.
10. Gordon KB, Papp KA, Hamilton TK, et al. 2003. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA, 290:3133-5.
11. Gordon KB, West DT. 2001. Biologic therapy in psoriasis. In: Wolverton S (ed). Comprehensive dermatologic drug therapy. Philadelphia, PA: WB Saunders Co, pp. 928-42.
12. Gottlieb AB, Matheson RT, Lowe N, et al. 2003a. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol, 139:1627-32.
13. Gottlieb AB, Chaudhari U, Mulcahy LD, et al. 2003b. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol, 48:829-35.
14. Gottlieb AB, Evans R, Li S, et al. 2004. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized double-blind, placebo-controlled trial. J Am Acad Dermatol, 51:534-42.
15. Gottlieb AB, Hamilton T, Caro I, et al. 2006. Efalizumab Study Group. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol, 54:5154-63.
16. Griffiths CEM, Barker JNWN. 2007. Pathogenesis and clinical features of psoriasis. Lancet, 370:263-71.
17. Hankin CS, Feldman SR, Szczotka A, et al. 2005. A cost comparison of treatments for moderate to severe psoriasis. Drug Ben Trends, 17:200-14.
18. Heenen M, Laporte M, Noel JC, et al. 1998. Methotrexate induces apoptotic cell death in human keratinocytes. Arch Dermatol Res, 290:240-5.
19. Hochberg MC, Lebwohl MG, Plevy SE, et al. 2005. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum, 34:819-36.
20. Hogg N, Laschinger M, Giles K, et al. 2003. T cell integrins: more than just sticking points. J Cell Sci, 116:4695-705.
21. Krueger G, Elewski B, Papp K, et al. 2006. Patients with psoriasis respond to continuous open-label Etanercept treatment after initial incomplete response in randomized, placebo controlled trial. J Am Acad Dermatol, 54:S112-9.
22. Lande R, Gregorio J, Facchinetti V, et al. 2007. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature, 449:564-9.
23. Langley RG, Carey WP, Rafal ES, et al. 2005. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther, 27:1317-28.
24. Lebwohl M, Tyring SK, Hamilton TK, et al.; Efalizumab Study Group. 2003. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med, 349:2004-13.
25. Leonardi CL, Powers JL, Matheson RT, et al. 2003. Etanercept as monotherapy in patients with psoriasis. N Engl J Med, 349:2014-22.
26. Lewis TG, Tuchinda HW, Lim HKW. 2005. Life-threatening pustolar and erythrodermic psoriasis responding to infliximab. J Drugs Dermatol, 5:546-8.
27. Liu Y, Krueger JG, Bowcock AM. 2007. Psoriasis: genetic associations and immune system changes. Genes Immun, 8:1-12.
28. Locksley RM, Killeen N, Lenardo MJ. 2001. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell, 104:487-501.
29. Magliocco MA, Gottlieb AB. 2004. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of three cases. J Am Acad Dermatol, 51:580-4.
30. Menter A, Gordon K, Carey W, et al. 2005. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol, 141:31-8.
31. Menter A, Feldman SR, Weinstein GD, et al. 2007. A randomized comparison of continuous vs. intermittent infliximab mainenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol, 56:31-44.
32. Menter A, Griffiths CE. 2007. Current and future management of psoriasis. Lancet, 370:272-84.
33. Mueller W, Herrmann B. 1979. Cyclosporin A for psoriasis. N Engl J Med, 301:555.
34. Nelson AA, Pearce DJ, Fleischer AB, et al. 2008. Cost-effectiveness of biological treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol, 58:125-5.
35. Ong PY, Ohtake T, Brandt C, et al. 2002. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med, 347:1151-60.
36. Papp KA, Tyring S, Lahfa M, et al. 2005. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol, 152:1304-12.
37. Papp KA. 2006. The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res, 298:7-15.
38. Pasparakis M, Curtois G, Hafner M, et al. 2002. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature, 417:861-6.
39. Pastore S, Mascia F, Mariani V, et al. 2006. Keratinocytes in skin inflammation. Expert Rev Dermatol, 1:279-91.
40. Pincelli C, Henninger E, Casset-Semanaz F. 2006. The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab. Arch Dermatol Res, 298:329-38.
41. Reich K, Nestle FO, Papp K, et al. 2005. EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet, 366:1367-74.
42. Robinson MR, Korman BD, Korman NJ. 2007. Combination immunosuppressive therapies. Arch Dermatol, 143:1053-7.
43. Rokhsar C, Rabhan N, Cohen SR. 2006. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol, 54:361-2.
44. Schon MP, Ludwig RJ. 2005. Lymphocyte trafficking to inflamed skin. Molecular mechanisms and implications for therapeutic target molecules. Expert Opin Ther Targets, 9:225-43.
45. Schwartz PM, Barnett SK, Attillasoy ES, et al. 1992. Methotrexate induces differentiation of human keratinocytes. Proc Natl Acad Sci U S A, 89:594-8.
46. Shikiar R, Willian MK, Okun MM, et al. 2006. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes, 4:71.
47. Skomsvoll JF, Wallenius M, Koksvik HS, et al. 2007. Drug Insight: antitumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation. Nat Clin Pract Rheumatol, 3:156-64.
48. Smith CH, Anstey AV, Barker JNWN, et al. 2005. British Association of Dermatology Guidelines for the use of biological interventions in psoriasis 2005. Br J Dermatol, 153:486-97.
49. Sterry W, Stingl G, Langley RG, et al.; CLEAR Multinational Study Group. 2006. Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trial. J Dtsch Dermatol Ges, 4:947-56.
50. Travers JB. 2000. Novel immunomodulators for topical skin disease therapy. Expert Opin Invest Drugs, 9:529-42.
51. Valdimarsson H. 2007. The genetic basis of psoriasis. Clin Dermatol, 25:563-7.
52. Wahie S, Alexandruff A, Reynolds NJ, et al. 2006. Psoriasis occurring after myeloablative therapy and autologous stem cell transplantation. Br J Dermatol, 154:194-5.
53. Weinberg JM. 2006. A review of the safety of the tumor necrosis inhibitors infliximab, etanercept, and adalimumab. In: Weinberg JM, Buchholz R, (Eds). TNF-alpha inhibitors. Basel: Birkhäuser, pp. 115-27.
54. Zeichner JA, Lebwohl M. 2007. Potential complications associated with the use of biologic agents for psoriasis. Dermatol Clin, 25:207-13.